Key Insights On Three FTSE Stocks – Hunting Plc, De La Rue Plc and GlaxoSmithKline Plc

  • Oct 30, 2019 GMT
  • Team Kalkine
Key Insights On Three FTSE Stocks – Hunting Plc, De La Rue Plc and GlaxoSmithKline Plc
Hunting Plc

Hunting Plc (HTG) is a London, the United Kingdom based Oil Equipment, Services & Distribution company engaged in the business of Well Construction, Well Completion, Well Intervention, and Exploration and Production. The company is involved in the production of equipment used in the exploration and production of oil and gas sector. Hunting’s products are designed for the usage in the operational phases in the wellbore from primary drilling to the eventual abandonment of the project. Production is done at spaces that are tactically positioned in terms of geography in the biggest oil and gas project across the world.

HTG Trading Update

On 29th October 2019, the company announced a trading update for the third quarter of the year. The company reported that the Board expects the FY 2019 Earnings before Interest Taxes, Depreciation and Amortisation (EBITDA) results to be at the lower side of the spectrum of anticipations of the market, with regard to the current trading cycle and the aggregate mix of results predicted for the remainder of this year.

HTG Share Price Performance

On 30th October 2019, at 01:00 P.M. GMT, while writing, Hunting Plc’s share price was trading at GBX 408.20 per share, a decrease of 1.87 per cent or GBX 7.80 per share as compared to the previous day’s closing price, which was reported to be at GBX 416.00 per share. While writing, the Hunting Plc stock was trading at a new 52-week low price, which was GBX 386.00 per share. Over this period, the stock price is down by 39.53 per cent. This was also 41.18 per cent below the 52-week high price at GBX 694.00 per share, which the company’s stock set on November 02, 2018. The company’s market capitalisation was reported to be at GBP 694.47 million.

By the time of writing, 131,060 of the company’s shares had been traded in the market. The average volume of trading per day, for the last one year in the market, was 443,410 stocks. The stock has reportedly lost 38.25 per cent in value in the last one year, from the price of GBX 661.00 per share. There has been a negative change in the last 6 months in the value of Hunting Plc’s stock of about 30.69 per cent from the price of GBX 589.00. The company’s stock has reportedly lost 10.95 per cent in value in the last one month from the price of GBX 458.4.

The beta of the company’s stock has been reported to be at 1.2762. Through this, it can be inferred that the movement in the company’s stock is more volatile, in comparison to the movement of the benchmark market index.

De La Rue Plc

De La Rue Plc (DLAR) is a Basingstoke, the United Kingdom based Industrial Support services company that is involved in producing and delivering banknotes to its clients like various governments and commercial organisations all across the globe. The company also engages in the business of providing services like Identity solutions, Product Authentication solutions and other services like cash cycle analytics and secure features.

DLAR Trading Update

On 30th October 2019, the company provided a trading update from 1st April 2019 to date. The company reported that it anticipates the adjusted operating profits for the H1 2019 ended 28th September 2019 to be approximately around lower to middle single-digit in millions. FY 2020 adjusted operating profit is expected to be majorly lower than market anticipations. The company also reported that the management, led by the new Chief Executive Officer of the group, is in the process of an overall review of the operations and is expected to announce the results for the first half of FY 2020 on 26 November 2019.

DLAR Share Price Performance

On 30th October 2019, at 12:50 A.M. GMT, while writing, De la Rue Plc’s share price was trading at GBX 150.10 per share, a decrease of 19.73 per cent or GBX 36.90 per share as compared to the previous day’s closing price, which was reported to be at GBX 187.00 per share. While writing, the De La Rue Plc stock was trading at a new 52-week low price, which was GBX 131.60 per share, in day’s trading session. At the current market price, the company’s stock was trading 70.75 per cent below the 52-week high price at GBX 513.32 per share, which the company’s stock set on November 08, 2018. The company’s market capitalisation was reported to be at GBP 194.38 million.

By the time of writing, 1.27 million of the company’s shares had been traded in the market. The average volume of trading per day, for the last one year in the market, was 231,220 stocks. The stock has reportedly lost 68.60 per cent in value in the last one year, from the price of GBX 478.00 per share. There has been a negative change in the last 6 months in the value of De La Rue Plc’s stock of about 66.07 per cent from the price of GBX 442.5. The company’s stock has also reportedly lost 32.84 per cent in value in the last one month from the price of GBX 223.50.

The beta of the company’s stock has been reported to be at 0.9408. Through this, it can be inferred that the movement in the company’s stock is less volatile, in comparison to the movement of the benchmark market index.

GlaxoSmithKline Plc

GlaxoSmithKline Plc (GSK) is a Brentford, the United Kingdom based pharmaceuticals and biotechnology company that is engaged in the business of developing and selling, pharmaceuticals and vaccinations across the world. The company is considered to be one of the biggest pharma companies in the world, and its products are sold worldwide. The company’s products include prescription medicine, vaccinations, consumer healthcare products as well as Stiefel Dermatology products.

GSK Financial Performance

On 30th October 2019, the company announced its third-quarter results for the year. The company highlighted Group sales to be at £9.4 billion an increase of 16 per cent AER and 11 per cent CER and Pro-forma increase of 6 per cent CER. It was also reported that the Pharmaceuticals business sales were at £4.5 billion at an increase of 7 per cent AER and 3 per cent CER. The vaccinations segment sales were reported to be at £2.3 billion a growth of 2 per cent AER and 15 per cent CER basis. It was also highlighted that the Consumer Healthcare segment sales were at £2.5 billion during the period, which was a growth of 30 per cent AER and 25 per cent CER. The total group operating margin was reported to be at 22.9 per cent and the Adjusted Group operating margin was reported to be at 29.7 per cent during the reporting period, in line with the growth in spending made on the Research and Development as well as on obtaining priority assets during the period, which became the driver of the growth for the company.

Q3 2019 results Q3 2019 Growth   9 months 2019 Growth  
  £m £% CER% £m £% CER%
Turnover 9,385  16 11 24,855  10 7
Total operating profit 2,147  12 3 5,059  29 20
Total earnings per share 31.4p 9 -1 67.7p 38 28
Adjusted operating profit 2,786  10 3 7,120  9 3
Adjusted earnings per share 38.6p 9 1 99.2p 12 7
Net cash from operating activities 2,515  21   4,567  6  
Free cash flow 1,939  25   2,474  4  

Source: Company Website

GSK Share Price Performance

On 30th October 2019, at 01:40 P.M. GMT, while writing, GlaxoSmithKline Plc’s share price was trading at GBX 1753.6 per share, an increase of 0.79 per cent or GBX 13.80 per share as compared to the previous day’s closing price, which was reported to be at GBX 1739.80 per share. While writing, the GlaxoSmithKline Plc stock was trading at a new 52-week high price, which was GBX 1788.20 per share, in day’s trading session. This was also 24.475 per cent above the 52-week low price at GBX 1408.8 per share, which the company’s stock set on December 06, 2018. The company’s market capitalisation was reported to be at GBP 86.793 billion.

By the time of writing, 3.00 million of the company’s shares had been traded in the market. The average volume of trading per day, for the last one year in the market, was 7.03 million stocks. The stock has reportedly gained 14.05 per cent in value in the last one year, from the price of GBX 1537.6 per share. There has been a positive change in the last 6 months in the value of GlaxoSmithKline Plc’s stock of about 11.453 per cent from the price of GBX 1573.40. The company’s stock has also reportedly gained 0.516 per cent in value in the last one month from the price of GBX 1744.6.

The beta of the company’s stock has been reported to be at 0.9475. Through this, it can be inferred that the movement in the company’s stock is marginally less volatile, in comparison to the movement of the benchmark market index.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK